NeuroPace, Inc.

NASDAQ•NPCE

CEO: Mr. Joel D. Becker

Sector: Healthcare

Industry: Medical - Devices

Listing Date: 2021-04-22

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

Contact Information

455 North Bernardo Avenue, Mountain View, CA, 94043, United States

650-237-2700

www.neuropace.com

Market Cap

$516.79M

P/E (TTM)

-23.4

23.6

Dividend Yield

52W High

$18.98

52W Low

$7.56

52W Range

68%

Rank64Top 94.9%

1.7

F-Score

Modified Piotroski Analysis

Based on 6-year fundamentals

Weak • 1.7 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2020-2025

Financial Dashboard

Q4 2025 Data

Revenue

$26.59M+0.00%

4-Quarter Trend

EPS

-$0.08+0.00%

4-Quarter Trend

FCF

$409.00K+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Strong Annual Revenue Growth Revenue reached 99.986M USD, up 25% from 79.906M USD in 2024, driven by increased RNS System units sold and service revenue.

Net Loss Narrowing Trend Net loss narrowed to 21.465M USD from 27.141M USD in 2024, reflecting a 21% improvement in bottom-line performance for the fiscal year.

Gross Margin Expansion Achieved Gross profit reached 77.220M USD, up 31% from 59.085M USD, with gross margin expanding to 77.2% from 73.9% due to production efficiencies.

Risk Factors

Single Product Revenue Reliance RNS System remains primary revenue source; failure to maintain market share or expand indications could negatively impact financial condition and future operations.

Regulatory Approval Delay Risks Pervasive FDA requirements and potential delays in indication expansion approvals could hinder growth potential and long-range financial plans for the company.

Supply Chain Vulnerability Concerns Dependence on limited single-source suppliers for key components creates risks of supply shortages and price fluctuations, potentially harming manufacturing and operations.

History of Recurring Losses Accumulated deficit reached 552.4M USD; continued net losses and debt obligations may impact ability to operate and secure future financing needs.

Outlook

Expanded Patient Population Focus Pursuing FDA approval for RNS System in patients with drug-resistant idiopathic generalized epilepsy and pediatric patients to broaden addressable market reach.

AI Technology Development Plans Developing AI-powered software tools like Seizure ID to enhance therapy effectiveness and provide actionable insights for clinicians to optimize patient care.

International Market Expansion Strategy Commenced limited sales in Israel and Canada; prioritizing regulatory approvals and reimbursement in international markets to drive long-term revenue growth.

Peer Comparison

Revenue (TTM)

TCMD

$329.52M

+12.5%

TMCI

$212.69M

+1.6%

CERS

$206.13M

+14.3%

Gross Margin (Latest Quarter)

SMLR

91.5%

+0.1pp

SGHT

87.3%

+2.5pp

CVRX

86.3%

+3.6pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
SRDX	$614.51M	-43.3	-12.8%	19.2%
BWAY	$587.17M	69.0	12.0%	6.0%
TCMD	$570.13M	29.4	9.3%	5.8%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

5.7%

Steady Growth

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

25%

Cash Flow Needs Attention

Deep Research

Next earnings:May 7, 2026

EPS:-$0.22

Revenue:$21.65M

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data